Intec Pharma (NTEC) Given Buy Rating at LADENBURG THALM/SH SH

Intec Pharma (NASDAQ:NTEC)‘s stock had its “buy” rating reaffirmed by analysts at LADENBURG THALM/SH SH in a note issued to investors on Thursday, AnalystRatings.com reports.

The analysts wrote, “We know the AP-cannabis compounds are so oily they require a reservoir, which is unlike the two immediate-release (IR) and one extended-release (XR) films in AP-CD/LD. So again, the films are specific to the API. Management has described AP’s technology as uniquely suited to low soluble drugs, but we do not know if that describes either of the two major pharma’s proprietary drugs.””

Several other research analysts have also weighed in on NTEC. Zacks Investment Research lowered Intec Pharma from a “hold” rating to a “sell” rating in a report on Wednesday, January 16th. BidaskClub lowered Intec Pharma from a “strong-buy” rating to a “buy” rating in a report on Wednesday, January 16th. ValuEngine upgraded Intec Pharma from a “hold” rating to a “buy” rating in a report on Monday, February 4th. Maxim Group reiterated a “buy” rating and set a $12.00 target price on shares of Intec Pharma in a report on Tuesday, February 19th. Finally, Oppenheimer set a $15.00 target price on Intec Pharma and gave the stock a “buy” rating in a report on Friday, February 22nd. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $12.17.

NTEC stock traded up $0.20 during midday trading on Thursday, hitting $5.48. 4,311 shares of the company’s stock were exchanged, compared to its average volume of 253,442. The firm has a market cap of $192.36 million, a PE ratio of -3.90 and a beta of 0.29. Intec Pharma has a one year low of $3.55 and a one year high of $9.25.

Intec Pharma (NASDAQ:NTEC) last posted its earnings results on Tuesday, May 7th. The biotechnology company reported ($0.32) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.37) by $0.05. On average, sell-side analysts expect that Intec Pharma will post -1.06 earnings per share for the current year.

Several institutional investors have recently modified their holdings of NTEC. PRW Wealth Management LLC acquired a new position in shares of Intec Pharma in the fourth quarter valued at approximately $29,000. Reilly Financial Advisors LLC acquired a new position in shares of Intec Pharma in the fourth quarter valued at approximately $38,000. BlackRock Inc. acquired a new position in shares of Intec Pharma in the fourth quarter valued at approximately $67,000. Marshall Wace North America L.P. acquired a new position in shares of Intec Pharma in the first quarter valued at approximately $117,000. Finally, Delek Group Ltd. acquired a new position in shares of Intec Pharma in the first quarter valued at approximately $154,000. Institutional investors own 34.90% of the company’s stock.

About Intec Pharma

Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism.

Featured Article: Candlestick

Analyst Recommendations for Intec Pharma (NASDAQ:NTEC)

Receive News & Ratings for Intec Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma and related companies with MarketBeat.com's FREE daily email newsletter.